designer491/iStock via Getty Images Additional data from an ongoing phase 1/2 trial on Vertex Pharmaceuticals' ( NASDAQ: VRTX ) VX-880 for type 1 diabetes showed a full, single infusion of the candidate led to islet cell engraftment and glucose-responsive insulin production by day 90. Also, all 12 patients who received the full dose achieved target HbA1c levels of <7.0%, while 11 of 12 patients reduced or eliminated use of exogenous insulin.
Vertex also noted that due to the positive results, it has expanded the study to ~37 participants. More on Vertex Pharmaceuticals Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Vertex Pharmaceuticals Incorporated (VRTX) The 44th Annual William Blair Growth Stock Conference Vertex inks a long-term coverage deal for cystic fibrosis drugs in England Alpine Immune ticks higher as HSR waiting period for Vertex Pharma deal expires.
